Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

Investors may react cautiously to news that PPLPHARMA's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.431000
forwardPE 48.001446
debtToEquity 60.083000
earningsGrowth 0.000000
revenueGrowth -0.088000
grossMargins 0.610460
operatingMargins -0.021600
trailingEps -0.200000
forwardEps 3.154280

PPLPHARMA's current ratio of 1.431 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as PPLPHARMA can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
Piramal Pharma Limited's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

Price projections for Piramal Pharma Limited have been revised downward over time, signaling decreasing optimism about the company's outlook. Analysts appear to be adjusting their expectations as concerns about future performance grow.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Analysts have shown a buy bias for Piramal Pharma Limited, marking it as a favorable investment option. This could inspire investors to see Piramal Pharma Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.